iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024
Summary
- iTeos Therapeutics, Inc.'s lead candidate, belrestotug, shows promising response rates in lung cancer but faces challenges with increased toxicity and skepticism due to past failures in similar approaches.
- The company's financial health is strong, with over half a billion dollars in liquid assets and long-term investments, providing a substantial cushion for ongoing projects.
- Despite shelving inupadenant, the focus remains on belrestotug, with ongoing trials exploring its potential in various cancer indications.
- Given the promising data and financial runway, I maintain a Buy sentiment on ITOS stock, despite the inherent risks and market pessimism.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.